---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-26-000006"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2026-02-10T23:59:59+00:00"
generated_at: "2026-05-16T03:30:47.225384+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Edwards Q4 sales $1.57B (+13.3%), TAVR +12%, TMTT >40% growth; FY2026 guidance raised

## Summary
- Q4 GAAP EPS $0.11, adjusted EPS $0.58; gross margin 78.1% (78.3% adjusted).
- TAVR sales $1.16B (+12.0%); TMTT sales $156M (+40%). Full-year sales growth 11.5%.
- FY2026 outlook: constant-currency sales growth 8–10%, adjusted EPS $2.90–$3.05.
- FDA approved SAPIEN M3, first transcatheter mitral replacement; CMS opened TAVR NCD reconsideration.
- Q1 2026 guidance: sales $1.55–$1.63B, adjusted EPS $0.70–$0.76.

## SEC filing metadata
- accession: 0001099800-26-000006
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2026-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000006/0001099800-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000006/ew-20260210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-26-000006
- JSON: https://secwatch.observer/filing/0001099800-26-000006.json
- Plain text: https://secwatch.observer/filing/0001099800-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.